Replies to post #3240 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Notes on today’s IP news:

1. The news is neutral for GTC.

2. GTC had originally licensed this nuclear-transfer patent from ACTC, but ACTC lost a patent case vs GERN and thereby lost ownership of the IP (#msg- 13128835).

3. Now, GTC has licensed the same patent from Start Licensing Inc. (i.e. GERN) for what is presumably a similar (small) royalty to what GTC would have paid ACTC.

4. The new license has no effect whatsoever on ATryn, which is produced using micro-injection rather than nuclear transfer.

Dew